Neil Desai, MD, associate professor of Radiation Oncology at UT Southwestern Medical Center, discusses key factors when considering whether a patient with bladder cancer is eligible to receive bladder-sparing surgery.
Enfortumab vedotin plus pembrolizumab improves survival in frontline urothelial cancer
September 22nd 2023The EV-302 trial is the confirmatory trial for the FDA’s accelerated approval of pembrolizumab plus enfortumab vedotin for the first-line treatment of patients with locally advanced or metastatic urothelial carcinoma.
Speaking of Urology Podcast: Dr. Ritch and Dr. Katz discuss new bladder cancer management app
December 7th 2021“It's not a replacement for clinical judgment, obviously. But at the end of the day, the idea is that it shows you what your next steps are based on what the American Urological Association and [Society of Urologic Oncology] guidelines are for non-muscle invasive bladder cancer,” Chad R. Ritch, MD, MBA, FACS.
2 Clarke Drive
Cranbury, NJ 08512